Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
641-660 of 998 trials

Telmisartan for Portal Hypertension in Liver Disease

We are studying whether telmisartan can lower liver pressure in patients with advanced chronic liver disease and portal hypertension. This trial will also assess its safety and impact on quality of life.

Compensated Advanced Chronic Liver DiseasePortal Hypertension3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteHepatologyInternal Medicine

Portosinusoidal Vascular Disorder: Edoxaban Study

We are studying the safety of edoxaban in patients with Portosinusoidal Vascular Disorder. The trial also explores its potential to prevent blood clots and improve quality of life.

Porto-Sinusoidal Vascular Disorder>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteCardiology

BRAF Mutated Melanoma: Encorafenib and Binimetinib with Cemiplimab and Fianlimab

We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.

Melanoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Type 2 Diabetes: Comparing Empagliflozin, Pioglitazone, and Semaglutide

We are studying how different diabetes medications affect fat tissue function in people with type 2 diabetes. This research may help us understand which drug works best for improving health outcomes.

Type 2 Diabetes6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology

Cardiovascular Disease Prevention: Personalized Statin Therapy

We are studying whether statin treatment guided by genetic risk can lower heart disease events in individuals at high risk. The trial will also look at how well patients accept this personalized approach and its effects on their health.

High Genetic Risk for Coronary Artery Disease1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Oxytocin Treatment for Autism in Children

We are studying whether multiple doses of oxytocin can improve social symptoms in children with autism and intellectual disability. The trial also looks at other behavioral changes and stress-related measurements.

Autism Spectrum Disorder6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePediatricsPsychiatry

CSL889 for Sickle Cell Disease: A New Treatment

We are studying the safety and effects of CSL889 in adults and adolescents with sickle cell disease during painful vaso-occlusive crises. The goal is to see if it helps speed up recovery compared to a placebo.

Sickle Cell Anemia with Crisis≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Preventing C. difficile Infections: Oral Vancomycin for Stem Cell Transplant Patients

We are studying if oral vancomycin can help prevent infections in patients receiving allogeneic stem cell transplants. This research aims to see if it reduces the risk of Clostridium difficile infections during their hospital stay.

Clostridium Difficile InfectionPatients Hospitalized for Allogeneic Hematopoietic Stem Cell Transplantation≤3 monthsConfirmation phase (III)Standard MedicinesPartially RemoteHematologyInfectious Diseases

Polymyalgia Rheumatica: Rituximab Study

We are investigating whether rituximab can help reduce the need for corticosteroids in people with relapsing polymyalgia rheumatica. This study compares rituximab to a placebo to assess its effectiveness.

Polymyalgia Rheumatica1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyRheumatology

Generalized Anxiety Disorder: MM120 Medication Study

We are testing a new oral medication, MM120, to see if it helps reduce anxiety symptoms in adults with generalized anxiety disorder. The study will also look at its effects on quality of life and sexual functioning.

Generalized Anxiety Disorder1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePsychiatry

BRAF Alterations in Cancer: FORE8394 Treatment Study

We are testing the drug FORE8394 in patients with advanced solid tumors or specific brain tumors that have BRAF alterations. The goal is to see if it can effectively treat these cancers.

BRAF Gene MutationEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Pulmonary Arterial Hypertension: LTP001 Treatment Study

We are studying a new treatment called LTP001 in healthy adults and in individuals with pulmonary arterial hypertension. The goal is to evaluate its safety and how well it may improve exercise capacity and overall health.

Pulmonary Arterial HypertensionSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Ataxia Telangiectasia: EryDex Safety Study

We are assessing the safety and tolerability of EryDex in individuals with Ataxia Telangiectasia. Additionally, we’re exploring its potential effects on neurological symptoms.

Ataxia Telangiectasia (A-T)1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Advanced Lung Cancer: Eftilagimod Alfa with Pembrolizumab

We are studying a new drug, eftilagimod alfa, combined with pembrolizumab and chemotherapy for patients with advanced non-small cell lung cancer. The goal is to see if this combination works better than standard treatments.

Advanced Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

Palmo-Plantars Warts: HPV Vaccine Study

We are testing a nonavalent HPV vaccine to see if it helps people with difficult-to-treat warts on their hands and feet. The study aims to improve wart clearance, pain, and overall quality of life.

HPV Vaccine>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteDermatologyInfectious Diseases

Obesity: PF-07976016 Medication Study

We are testing a new medication called PF-07976016 to see if it helps adults with obesity lose weight more effectively than a placebo. The study also looks at the safety of this medication for those already taking liraglutide.

ObesityOverweight6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteDiabetologyEndocrinology

Metastatic Colorectal Cancer: Trifluridine/Tipiracil with Panitumumab vs. Bevacizumab

We are studying two treatment combinations to find out which one works better for people with metastatic colorectal cancer. The trial also looks at safety and how treatments affect patients' quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer Prevention: Denosumab for Women with BRCA1 Mutation

We are studying whether Denosumab can help prevent breast cancer in women carrying a BRCA1 mutation. This trial compares its effects to a placebo to see if it reduces cancer risk.

Breast Cancer Prevention in BRCA1 Mutation Carriers>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteHematologyOncology

IDH1/IDH2-Mutant Glioma: Vorasidenib with Temozolomide

We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.

IDH1-mutant GliomaIDH2-mutant Glioma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sickle Cell Disease: Hydroxycarbamide Tablets for Children

We are studying the effects of a twice-daily dose of Hydroxycarbamide in children with sickle cell disease. This trial aims to evaluate its safety, effectiveness, and how well children tolerate the treatment.

Sickle Cell Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics